Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

Annals of Oncology

Volumn 29, Issue 6, 2018, Pages 1437-1444

  Derosa, L ^a,b,c   Hellmann, M D ^d,e,f   Spaziano, M ^g   Halpenny, D ^d   Fidelle, M ^a,b,c   Rizvi, H ^d   Long, N ^d   Plodkowski, A J ^d   Arbour, K C ^d   Chaft, J E ^d,e   Rouche, J A ^h   Zitvogel, L ^a,b,c,i   Zalcman, G ^j   Albiges, L ^a,c,h,k   Escudier, B ^a,h,k   Routy, Bertrand ^a,b,c,l  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b University Paris XI   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f Parker Institute for Cancer Immunotherapy   (United States)

^g MCGILL UNIVERSITY   (Canada)

^h Department of Imaging ^*  (France)

ⁱ Center of Clinical Investigations in Biotherapies of Cancer (CICBT)   (France)

^j BICHAT HOSPITAL   (France)

^k Faculty of Medicine University of Paris Sud   (France)

^l CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

Antibiotics; Immune checkpoint inhibitors; Microbiota; Non small cell lung cancer; Renal cell carcinoma

Indexed keywords

BETA LACTAM ANTIBIOTIC; BEVACIZUMAB; EVEROLIMUS; NIVOLUMAB; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RENAL CELL CARCINOMA; URINARY TRACT INFECTION; ADVERSE EVENT; CELL CYCLE CHECKPOINT; DRUG EFFECT; DYSBIOSIS; FOLLOW UP; IMMUNOTHERAPY; KIDNEY TUMOR; LUNG TUMOR; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CELL CYCLE CHECKPOINTS; DYSBIOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; NIVOLUMAB; PROGNOSIS; SURVIVAL RATE;

EID: 85050806220     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy103     Document Type: Article

References (34)

1. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803-1813
2. Escudier B, Sharma P, McDermott DF et al. CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol 2017 Mar 3 [Epub ahead of print], DOI: 10.1016/j.eururo.2017.02.010
3. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373(17): 1627-1639
4. Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375(19): 1823-1833
5. Carbone DP, ReckM, Paz-Ares L et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl JMed 2017; 376(25): 2415-2426
6. Patel SP, Kurzrock R. PD-L1 Expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015; 14(4): 847-856
7. Gao J, Shi LZ, Zhao H et al. Loss of IFN-c pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 2016; 167(2): 397-404.e9
8. AyersM, Lunceford J, NebozhynMet al. IFN-c-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 2017; 127(8): 2930-2940
9. Vétizou M, Pitt JM, Daillère R et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350(6264): 1079-1084
10. Routy B, Le Chatelier E, Derosa L et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2017 Nov 2 [Epub ahead of print], DOI: 10.1126/science.aan3706
11. Lozupone CA, Stombaugh JI, Gordon JI et al. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489(7415): 220-230
12. Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and anticancer immunosurveillance. Cell 2016; 165(2): 276-287
13. Ubeda C, Pamer EG. Antibiotics, microbiota, and immune defense. Trends Immunol 2012; 33(9): 459-466
14. Lange K, Buerger M, Stallmach A, Bruns T. Effects of antibiotics on gut microbiota. Dig Dis 2016; 34(3): 260-268
15. Korpela K, de Vos WM. Antibiotic use in childhood alters the gut microbiota and predisposes to overweight. Microb Cell 2016; 3(7): 296-298
16. Leclercq S, Mian FM, Stanisz AM et al. Low-dose penicillin in early life induces long-term changes in murine gut microbiota, brain cytokines and behavior. Nat Commun 2017; 8: 15062
17. Arrieta M-C, Stiemsma LT, Dimitriu PA et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci Transl Med 2015; 7: 307ra152
18. Iacovelli R, Lanoy E, Albiges L, Escudier B. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int 2012; 110(11): 1747-1753
19. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990 2009; 45: 228-247
20. Jakobsson HE, Jernberg C, Andersson AF et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One 2010; 5(3): e9836
21. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007; 1: 56-66
22. Matson V, Fessler J, Bao R et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018; 359(6371): 104-108
23. Gopalakrishnan V, Spencer CN, Nezi L et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2017 Nov 2 [Epub ahead of print], DOI: 10.1126/science.aan4236
24. Ferris RL, Blumenschein G, Harrington K et al. Abstract CT022: evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: analyses from CheckMate 141. Cancer Res. 2017; 77(13 Suppl): CT022-CT022
25. Dubin K, Callahan MK, Ren B et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 2016; 7: 10391
26. Chaput N, Lepage P, Coutzac C et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol Off J Eur Soc Med Oncol 2017; 28(suppl_5): 1368-1379
27. Hammers HJ, Plimack ER, Infante JR et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 Study. J Clin Oncol 2017; 35(34): 3851-3858
28. Motzer RJ, Rini BI, McDermott DF et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015; 33(13): 1430-1437
29. Meeting Library j Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Results from the NIVOREN GETUG-AFU 26 study. https://meetinglibrary.asco.org/record/157690/abstract (3 March 2018, date last accessed)
30. Iida N, Dzutsev A, Stewart CA et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342(6161): 967-970
31. Viaud S, Saccheri F, Mignot G et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342(6161): 971-976
32. Rosa RG, Goldani LZ, dos Santos RP. Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort study. BMC Infect Dis 2014; 14(1): 286
33. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330(17): 1240-1241
34. Montassier E, Batard E, Gastinne T et al. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013; 32(7): 841-850